Which has stronger earnings and valuation, IMMP or KTTA?

Pasithea Therapeutics has lower revenue, but higher earnings than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $6.69M 8.97 -$39.78M N/A N/A Pasithea Therapeutics N/A N/A -$20.43M -$2.08 N/A

Is IMMP or KTTA more profitable?

Prima BioMed's return on equity of 0.00% beat Pasithea Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Prima BioMed N/A N/A N/A Pasithea Therapeutics N/A -57.44% -53.61%

Does the media prefer IMMP or KTTA?

In the previous week, Prima BioMed had 17 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 20 mentions for Prima BioMed and 3 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 0.97 beat Prima BioMed's score of 0.11 indicating that Pasithea Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prima BioMed 0 Very Positive mention(s) 1 Positive mention(s) 18 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pasithea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, KTTA or PMVP?

PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pasithea Therapeutics N/A N/A -$20.43M -$2.08 N/A PMV Pharmaceuticals N/A N/A -$77.74M -$1.49 N/A

Is KTTA or PMVP more profitable?

Pasithea Therapeutics' return on equity of -57.44% beat PMV Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Pasithea Therapeutics N/A -57.44% -53.61% PMV Pharmaceuticals N/A -68.98% -62.70%

Which has better valuation and earnings, CING or KTTA?

Cingulate is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cingulate N/A N/A -$22.45M -$4.23 N/A Pasithea Therapeutics N/A N/A -$20.43M -$2.08 N/A

Is CING or KTTA more profitable?

Pasithea Therapeutics' return on equity of -57.44% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Cingulate N/A -365.15% -158.55% Pasithea Therapeutics N/A -57.44% -53.61%

Does the media prefer CING or KTTA?

In the previous week, Cingulate had 13 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 16 mentions for Cingulate and 3 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 0.97 beat Cingulate's score of 0.68 indicating that Pasithea Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cingulate 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Pasithea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend KTTA or BYSI?

Pasithea Therapeutics presently has a consensus price target of $3.00, suggesting a potential upside of 370.07%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Pasithea Therapeutics is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pasithea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is KTTA or BYSI more profitable?

BeyondSpring's return on equity of 0.00% beat Pasithea Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pasithea Therapeutics N/A -57.44% -53.61% BeyondSpring N/A N/A -14.00%

Does the media favor KTTA or BYSI?

In the previous week, Pasithea Therapeutics and Pasithea Therapeutics both had 3 articles in the media. Pasithea Therapeutics' average media sentiment score of 0.97 beat BeyondSpring's score of 0.93 indicating that Pasithea Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pasithea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeyondSpring 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Pasithea Therapeutics (KTTA) Competitors

$0.64 -0.01 (-1.05%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$0.66 +0.02 (+3.57%)

As of 06/3/2026 07:55 PM Eastern

Compare

KTTA vs. MNOV, IMMP, PMVP, CING, and BYSI

Should you buy Pasithea Therapeutics stock or one of its competitors? MarketBeat compares Pasithea Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pasithea Therapeutics include MediciNova (MNOV), Prima BioMed (IMMP), PMV Pharmaceuticals (PMVP), Cingulate (CING), and BeyondSpring (BYSI). These companies are all part of the "pharmaceutical products" industry.

How does Pasithea Therapeutics compare to MediciNova?

Pasithea Therapeutics (NASDAQ:KTTA) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

In the previous week, Pasithea Therapeutics had 2 more articles in the media than MediciNova. MarketBeat recorded 3 mentions for Pasithea Therapeutics and 1 mentions for MediciNova. MediciNova's average media sentiment score of 1.89 beat Pasithea Therapeutics' score of 0.97 indicating that MediciNova is being referred to more favorably in the news media.

Company	Overall Sentiment
Pasithea Therapeutics	Positive
MediciNova	Very Positive

Pasithea Therapeutics has a net margin of 0.00% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-57.44%	-53.61%
MediciNova	-1,962.98%	-27.28%	-25.24%

Pasithea Therapeutics presently has a consensus price target of $3.00, suggesting a potential upside of 370.07%. MediciNova has a consensus price target of $7.50, suggesting a potential upside of 463.91%. Given MediciNova's stronger consensus rating and higher probable upside, analysts clearly believe MediciNova is more favorable than Pasithea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

Pasithea Therapeutics has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, MediciNova has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 9.9% of MediciNova shares are owned by institutional investors. 2.0% of Pasithea Therapeutics shares are owned by company insiders. Comparatively, 14.0% of MediciNova shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

MediciNova has higher revenue and earnings than Pasithea Therapeutics. MediciNova is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A
MediciNova	$410K	159.66	-$12M	-$0.23	N/A

Summary

MediciNova beats Pasithea Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Prima BioMed?

Prima BioMed (NASDAQ:IMMP) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

2.3% of Prima BioMed shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 3.1% of Prima BioMed shares are owned by insiders. Comparatively, 2.0% of Pasithea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Prima BioMed currently has a consensus price target of $5.50, indicating a potential upside of 1,251.35%. Pasithea Therapeutics has a consensus price target of $3.00, indicating a potential upside of 370.07%. Given Prima BioMed's higher probable upside, research analysts clearly believe Prima BioMed is more favorable than Pasithea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Prima BioMed has a beta of 2.21, suggesting that its share price is 121% more volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

In the previous week, Prima BioMed had 17 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 20 mentions for Prima BioMed and 3 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 0.97 beat Prima BioMed's score of 0.11 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prima BioMed	0 Very Positive mention(s)	1 Positive mention(s)	18 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pasithea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pasithea Therapeutics has lower revenue, but higher earnings than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$6.69M	8.97	-$39.78M	N/A	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A

Prima BioMed's return on equity of 0.00% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
Pasithea Therapeutics	N/A	-57.44%	-53.61%

Summary

Prima BioMed beats Pasithea Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Pasithea Therapeutics compare to PMV Pharmaceuticals?

Pasithea Therapeutics (NASDAQ:KTTA) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Pasithea Therapeutics' return on equity of -57.44% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-57.44%	-53.61%
PMV Pharmaceuticals	N/A	-68.98%	-62.70%

Pasithea Therapeutics currently has a consensus price target of $3.00, suggesting a potential upside of 370.07%. PMV Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 331.03%. Given Pasithea Therapeutics' higher probable upside, equities research analysts plainly believe Pasithea Therapeutics is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Pasithea Therapeutics had 2 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 3 mentions for Pasithea Therapeutics and 1 mentions for PMV Pharmaceuticals. PMV Pharmaceuticals' average media sentiment score of 1.80 beat Pasithea Therapeutics' score of 0.97 indicating that PMV Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Pasithea Therapeutics	Positive
PMV Pharmaceuticals	Very Positive

23.9% of Pasithea Therapeutics shares are held by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are held by institutional investors. 2.0% of Pasithea Therapeutics shares are held by insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Pasithea Therapeutics has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A

Summary

PMV Pharmaceuticals beats Pasithea Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Cingulate?

Cingulate (NASDAQ:CING) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

In the previous week, Cingulate had 13 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 16 mentions for Cingulate and 3 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 0.97 beat Cingulate's score of 0.68 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cingulate	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Pasithea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cingulate presently has a consensus target price of $28.33, suggesting a potential upside of 480.60%. Pasithea Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 370.07%. Given Cingulate's stronger consensus rating and higher possible upside, equities research analysts plainly believe Cingulate is more favorable than Pasithea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cingulate has a beta of -0.85, indicating that its stock price is 185% less volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market.

Pasithea Therapeutics' return on equity of -57.44% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-365.15%	-158.55%
Pasithea Therapeutics	N/A	-57.44%	-53.61%

Cingulate is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A

41.3% of Cingulate shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 4.3% of Cingulate shares are owned by company insiders. Comparatively, 2.0% of Pasithea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Pasithea Therapeutics beats Cingulate on 7 of the 13 factors compared between the two stocks.

How does Pasithea Therapeutics compare to BeyondSpring?

Pasithea Therapeutics (NASDAQ:KTTA) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

Pasithea Therapeutics presently has a consensus price target of $3.00, suggesting a potential upside of 370.07%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Pasithea Therapeutics is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BeyondSpring has higher revenue and earnings than Pasithea Therapeutics. BeyondSpring is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A
BeyondSpring	$1.75M	41.07	-$1.01M	-$0.14	N/A

In the previous week, Pasithea Therapeutics and Pasithea Therapeutics both had 3 articles in the media. Pasithea Therapeutics' average media sentiment score of 0.97 beat BeyondSpring's score of 0.93 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pasithea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeyondSpring	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pasithea Therapeutics has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market.

BeyondSpring's return on equity of 0.00% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-57.44%	-53.61%
BeyondSpring	N/A	N/A	-14.00%

23.9% of Pasithea Therapeutics shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 2.0% of Pasithea Therapeutics shares are held by insiders. Comparatively, 29.3% of BeyondSpring shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

BeyondSpring beats Pasithea Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Pasithea Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KTTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KTTA vs. The Competition

Export

Metric	Pasithea Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$16.09M	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-0.31	17.78	22.39	24.18
Price / Sales	N/A	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	0.27	6.63	9.84	6.72
Net Income	-$20.43M	$24.20M	$3.57B	$337.19M
7 Day Performance	-8.20%	-4.39%	-2.46%	-0.74%
1 Month Performance	N/A	N/A	N/A	-1.69%
1 Year Performance	-30.02%	45.50%	26.49%	33.10%

Pasithea Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KTTA Pasithea Therapeutics	2.9092 of 5 stars	$0.64 -1.1%	$3.00 +370.1%	-30.6%	$16.09M	N/A	N/A	3	News Coverage Analyst Upgrade
MNOV MediciNova	3.6124 of 5 stars	$1.33 -2.9%	$7.50 +463.9%	-5.7%	$67.43M	$410K	N/A	10	High Trading Volume
IMMP Prima BioMed	2.6616 of 5 stars	$0.43 -4.2%	$5.50 +1,165.5%	-78.1%	$66.86M	$6.69M	N/A	2,021	Trending News
PMVP PMV Pharmaceuticals	2.9516 of 5 stars	$1.20 -2.4%	$5.00 +316.7%	+26.2%	$65.60M	N/A	N/A	50	News Coverage
CING Cingulate	3.048 of 5 stars	$3.96 -17.2%	$28.33 +615.5%	+22.6%	$64.38M	N/A	N/A	20	News Coverage Options Volume High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KTTA) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pasithea Therapeutics (KTTA) Competitors

KTTA vs. MNOV, IMMP, PMVP, CING, and BYSI

How does Pasithea Therapeutics compare to MediciNova?

Summary

How does Pasithea Therapeutics compare to Prima BioMed?

Summary

How does Pasithea Therapeutics compare to PMV Pharmaceuticals?

Summary

How does Pasithea Therapeutics compare to Cingulate?

Summary

How does Pasithea Therapeutics compare to BeyondSpring?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KTTA vs. The Competition

Pasithea Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pasithea Therapeutics (KTTA) Competitors

KTTA vs. MNOV, IMMP, PMVP, CING, and BYSI

How does Pasithea Therapeutics compare to MediciNova?

Does the media favor KTTA or MNOV?

Is KTTA or MNOV more profitable?

Do analysts prefer KTTA or MNOV?

Which has more volatility & risk, KTTA or MNOV?

Do insiders and institutionals have more ownership in KTTA or MNOV?

Which has preferable earnings and valuation, KTTA or MNOV?

Summary

How does Pasithea Therapeutics compare to Prima BioMed?

Do institutionals & insiders believe in IMMP or KTTA?

Do analysts recommend IMMP or KTTA?

Which has more risk & volatility, IMMP or KTTA?

Does the media prefer IMMP or KTTA?

Which has stronger earnings and valuation, IMMP or KTTA?

Is IMMP or KTTA more profitable?

Summary

How does Pasithea Therapeutics compare to PMV Pharmaceuticals?

Is KTTA or PMVP more profitable?

Do analysts rate KTTA or PMVP?

Does the media prefer KTTA or PMVP?

Do insiders & institutionals have more ownership in KTTA or PMVP?

Which has more volatility & risk, KTTA or PMVP?

Which has better earnings & valuation, KTTA or PMVP?

Summary

How does Pasithea Therapeutics compare to Cingulate?

Does the media prefer CING or KTTA?

Do analysts prefer CING or KTTA?

Which has more volatility & risk, CING or KTTA?

Is CING or KTTA more profitable?

Which has better valuation and earnings, CING or KTTA?

Do insiders and institutionals have more ownership in CING or KTTA?

Summary

How does Pasithea Therapeutics compare to BeyondSpring?

Do analysts recommend KTTA or BYSI?

Which has preferable earnings and valuation, KTTA or BYSI?

Does the media favor KTTA or BYSI?

Which has more risk & volatility, KTTA or BYSI?

Is KTTA or BYSI more profitable?

Do institutionals & insiders have more ownership in KTTA or BYSI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KTTA vs. The Competition

Pasithea Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools